Wire · opportunities
Teclistamab plus daratumumab shows 18-point survival gain at 3 years in multiple myeloma
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 25 September 2026 · Fusion42 review
Teclistamab combined with daratumumab demonstrates an 18-percentage-point survival advantage at three years over standard daratumumab-based regimens in multiple myeloma patients with one to three prior therapy lines, suggesting a beneficial shift in early-line treatment.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You must prepare for a major shift in multiple myeloma treatment standards as survival rates improve markedly with teclistamab plus daratumumab. Early-stage biotech founders in oncology should explore partnerships or innovations targeting earlier therapy lines to capture this expanding market window.
◆ Coverage
1 source · 25 Sep 2026
◆ Related on Wire
◆ Topics